Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

ny and other third parties, which are the properties of their respective owners.

For more information about the Company, please visit http://www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre Vascular management believes that in order to properly understand the Company's short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. In addition, management uses results of operations before such items to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported a non-GAAP measure which excludes certain non-recurring expenses related to restructuring and to impairment. During 2007, the Company elected to terminate its exclusive distributor in Italy prior to the scheduled expiration of the related distribution contract and entered into a separation agreement with this distributor. The Company incurred charges of $254,000 in connection with this transaction in Q1 2008. Also, in Q1 2008, shortly following its acquisition of Biomateriali, the Company became aware of facts leading it to conclude that certain acquired inventory and intangibles should be written down, the inventory by $105,000 in Q4 2007 and the intangibles by $435,000 in Q1 2008. In Q1 2008 the Company undertook a reduction in force of 32 employees and incurred charges
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Brady ... GHS Label Guide . To align chemical container labeling with OSHA’s updated ... explanations of label components, an example of an accurate label, and pictogram uses ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... Delcath Systems, Inc. (Nasdaq: DCTH ), ... Perfusion ("PHP") System for the treatment of cancers of the ... 92) of patients have been enrolled in the Phase III ... liver. The eleven participating cancer centers in this trial ...
... India, December 11 , - SCRIP Awards Recognises ... and Biotech Industries Worldwide, - Glenmark is ... Prestigious Recognition, , ... at a glittering ceremony in London at the 2008 SCRIP Awards ...
... Board to Take Immediate Action to Protect and Maximize Shareholder Value ... Biotechnology Value Fund, L.P., the owner, together with its affiliates, of ... Inc. (Nasdaq: AVGN ) announced today that it had ... with Avigen,s recent performance and continued destruction of shareholder value. ...
Cached Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... tell us a lot about the way species evolve after ... exceptionally broad study conducted in part by Florida State University ... the evolutionary history of rodents calls into doubt a generally ... such as a continent, evolution leads to a dramatic increase ...
... A new study shows that immune cells outside the ... presented today at the American College of Neuropsychopharmacology (ACNP) Annual ... impact on the quality of life, health and life expectancy ... of the disorder remain something of a mystery. In ...
... between genes and the environment has been pondered at least ... mid-1800s. But until the arrival of modern genomic sequencing ... environment had on a species, genetic makeup. Now, researchers ... flies that live on opposite slopes of a unique natural ...
Cached Biology News:Study of rodent family tree puts brakes on commonly held understanding of evolution 2Study of rodent family tree puts brakes on commonly held understanding of evolution 3Peripheral immune system may regulate vulnerability to depression 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 3
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
... Anti-MAGE-D2/NRAGE-Like 2b GenBank ... Immunogen : peptide (C-QSQENQDTRPKVKAKK), corresponding ... human MAGE-D2/NRAGE-Like 2b Formulation: antiserum ... 30% glycerol Quality Assurance: routinely ...
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: